Phase III clinical trials of Kamailio DMQ
For immediate release: GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication. In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms. The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource. The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population." As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort: "Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity." Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms. Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch. Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives." Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial. "The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method." Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously. -- Alex Balashov | Principal | Evariste Systems LLC Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/
GPT-3? Happy April Fools Day. Brandon
On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com> wrote:
?For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication.
In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms.
The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population."
As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
-- Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system? ? Sent from mobile, with due apologies for brevity and errors.
On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com> wrote:
?GPT-3? Happy April Fools Day.
Brandon
On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com> wrote:
?For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication.
In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms.
The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population."
As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
-- Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
No AI here... This is classic, small-batch, hand-crafted, free-range, organic, gluten-free content. David -----Original Message----- From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex Balashov Sent: Thursday, April 1, 2021 12:18 PM To: Brandon Svec <bsvec at teamonesolutions.com> Cc: voiceops at voiceops.org Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system? ? Sent from mobile, with due apologies for brevity and errors.
On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com> wrote:
?GPT-3? Happy April Fools Day.
Brandon
On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com> wrote:
?For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication.
In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms.
The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population."
As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
-- Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops ---------------------------------------------------------------------- This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, notify the sender immediately by return email and delete the message and any attachments from your system.
Maybe they should open their eyes instead of doing a double-blind study! LOL! MARY LOU CAREY BackUP Telecom Consulting Office: 615-791-9969 Cell: 615-796-1111 On 2021-04-01 02:27 PM, Hiers, David wrote:
No AI here... This is classic, small-batch, hand-crafted, free-range, organic, gluten-free content.
David
-----Original Message----- From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex Balashov Sent: Thursday, April 1, 2021 12:18 PM To: Brandon Svec <bsvec at teamonesolutions.com> Cc: voiceops at voiceops.org Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system?
? Sent from mobile, with due apologies for brevity and errors.
On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com> wrote:
?GPT-3? Happy April Fools Day.
Brandon
On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com> wrote:
?For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication.
In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms.
The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population."
As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
-- Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
---------------------------------------------------------------------- This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, notify the sender immediately by return email and delete the message and any attachments from your system. _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
Right? Where do they find all these blind doctors? On Thu, Apr 1, 2021 at 12:37 PM Mary Lou Carey <marylou at backuptelecom.com> wrote:
Maybe they should open their eyes instead of doing a double-blind study! LOL!
MARY LOU CAREY BackUP Telecom Consulting Office: 615-791-9969 Cell: 615-796-1111
On 2021-04-01 02:27 PM, Hiers, David wrote:
No AI here... This is classic, small-batch, hand-crafted, free-range, organic, gluten-free content.
David
-----Original Message----- From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex Balashov Sent: Thursday, April 1, 2021 12:18 PM To: Brandon Svec <bsvec at teamonesolutions.com> Cc: voiceops at voiceops.org Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system?
? Sent from mobile, with due apologies for brevity and errors.
On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com> wrote:
?GPT-3? Happy April Fools Day.
Brandon
On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com> wrote:
?For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication.
In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms.
The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population."
As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
-- Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
---------------------------------------------------------------------- This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, notify the sender immediately by return email and delete the message and any attachments from your system. _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
ROFL Anyone paying attention to measured in kilograms ? Happy April ! ?Fools? -- J. Hellenthal The fact that there's a highway to Hell but only a stairway to Heaven says a lot about anticipated traffic volume.
On Apr 1, 2021, at 14:42, Carlos Alvarez <caalvarez at gmail.com> wrote:
? Right? Where do they find all these blind doctors?
On Thu, Apr 1, 2021 at 12:37 PM Mary Lou Carey <marylou at backuptelecom.com> wrote: Maybe they should open their eyes instead of doing a double-blind study! LOL!
MARY LOU CAREY BackUP Telecom Consulting Office: 615-791-9969 Cell: 615-796-1111
On 2021-04-01 02:27 PM, Hiers, David wrote:
No AI here... This is classic, small-batch, hand-crafted, free-range, organic, gluten-free content.
David
-----Original Message----- From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex Balashov Sent: Thursday, April 1, 2021 12:18 PM To: Brandon Svec <bsvec at teamonesolutions.com> Cc: voiceops at voiceops.org Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system?
? Sent from mobile, with due apologies for brevity and errors.
On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com> wrote:
?GPT-3? Happy April Fools Day.
Brandon
On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com> wrote:
?For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication.
In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms.
The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population."
As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
-- Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
---------------------------------------------------------------------- This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, notify the sender immediately by return email and delete the message and any attachments from your system. _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
GMO? On Thu, Apr 1, 2021 at 12:27 PM Hiers, David <David.Hiers at cdk.com> wrote:
No AI here... This is classic, small-batch, hand-crafted, free-range, organic, gluten-free content.
David
-----Original Message----- From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex Balashov Sent: Thursday, April 1, 2021 12:18 PM To: Brandon Svec <bsvec at teamonesolutions.com> Cc: voiceops at voiceops.org Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system?
? Sent from mobile, with due apologies for brevity and errors.
On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com> wrote:
?GPT-3? Happy April Fools Day.
Brandon
On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com> wrote:
?For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication.
In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms.
The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population."
As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
-- Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
---------------------------------------------------------------------- This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, notify the sender immediately by return email and delete the message and any attachments from your system. _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
Not GMO, but probably alcohol-infused. From: Carlos Alvarez <caalvarez at gmail.com> Sent: Thursday, April 1, 2021 12:36 PM To: Hiers, David <David.Hiers at cdk.com> Cc: Alex Balashov <abalashov at evaristesys.com>; Brandon Svec <bsvec at teamonesolutions.com>; voiceops at voiceops.org Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ GMO? On Thu, Apr 1, 2021 at 12:27 PM Hiers, David <David.Hiers at cdk.com<mailto:David.Hiers at cdk.com>> wrote: No AI here... This is classic, small-batch, hand-crafted, free-range, organic, gluten-free content. David -----Original Message----- From: VoiceOps <voiceops-bounces at voiceops.org<mailto:voiceops-bounces at voiceops.org>> On Behalf Of Alex Balashov Sent: Thursday, April 1, 2021 12:18 PM To: Brandon Svec <bsvec at teamonesolutions.com<mailto:bsvec at teamonesolutions.com>> Cc: voiceops at voiceops.org<mailto:voiceops at voiceops.org> Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system? ? Sent from mobile, with due apologies for brevity and errors.
On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com<mailto:bsvec at teamonesolutions.com>> wrote:
?GPT-3? Happy April Fools Day.
Brandon
On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com<mailto:abalashov at evaristesys.com>> wrote:
?For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication.
In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms.
The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population."
As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
-- Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/<https://urldefense.proofpoint.com/v2/url?u=http-3A__www.evaristesys.com_&d=DwMFaQ&c=N13-TaG7c-EYAiUNohBk74oLRjUiBTwVm-KSnr4bPSc&r=-GzOCp0ppLaBQPFaZ7lZ4bUUBQxpFBukitRP75oaRdQ&m=gnO2gWBU4p_DvqfSa2L3MHseBkydYAdKzY0qew1X6MQ&s=xzBexeqAoA52jVqCDX-rXmHrKGu7bR14O76kxMpGj7I&e=>, http://www.csrpswitch.com/<https://urldefense.proofpoint.com/v2/url?u=http-3A__www.csrpswitch.com_&d=DwMFaQ&c=N13-TaG7c-EYAiUNohBk74oLRjUiBTwVm-KSnr4bPSc&r=-GzOCp0ppLaBQPFaZ7lZ4bUUBQxpFBukitRP75oaRdQ&m=gnO2gWBU4p_DvqfSa2L3MHseBkydYAdKzY0qew1X6MQ&s=kHNFf5RrmT_Xo3TImrjO6ccBrRRJFN_B761MVAH0HeM&e=> _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org<mailto:VoiceOps at voiceops.org> https://puck.nether.net/mailman/listinfo/voiceops<https://urldefense.proofpoint.com/v2/url?u=https-3A__puck.nether.net_mailman_listinfo_voiceops&d=DwMFaQ&c=N13-TaG7c-EYAiUNohBk74oLRjUiBTwVm-KSnr4bPSc&r=-GzOCp0ppLaBQPFaZ7lZ4bUUBQxpFBukitRP75oaRdQ&m=gnO2gWBU4p_DvqfSa2L3MHseBkydYAdKzY0qew1X6MQ&s=7VvT9MpO5qABJ8iF-lKtFRSW8WpRO81Kqgr9qsK6ldU&e=>
VoiceOps mailing list VoiceOps at voiceops.org<mailto:VoiceOps at voiceops.org> https://puck.nether.net/mailman/listinfo/voiceops<https://urldefense.proofpoint.com/v2/url?u=https-3A__puck.nether.net_mailman_listinfo_voiceops&d=DwMFaQ&c=N13-TaG7c-EYAiUNohBk74oLRjUiBTwVm-KSnr4bPSc&r=-GzOCp0ppLaBQPFaZ7lZ4bUUBQxpFBukitRP75oaRdQ&m=gnO2gWBU4p_DvqfSa2L3MHseBkydYAdKzY0qew1X6MQ&s=7VvT9MpO5qABJ8iF-lKtFRSW8WpRO81Kqgr9qsK6ldU&e=> ---------------------------------------------------------------------- This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, notify the sender immediately by return email and delete the message and any attachments from your system. _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org<mailto:VoiceOps at voiceops.org> https://puck.nether.net/mailman/listinfo/voiceops<https://urldefense.proofpoint.com/v2/url?u=https-3A__puck.nether.net_mailman_listinfo_voiceops&d=DwMFaQ&c=N13-TaG7c-EYAiUNohBk74oLRjUiBTwVm-KSnr4bPSc&r=-GzOCp0ppLaBQPFaZ7lZ4bUUBQxpFBukitRP75oaRdQ&m=gnO2gWBU4p_DvqfSa2L3MHseBkydYAdKzY0qew1X6MQ&s=7VvT9MpO5qABJ8iF-lKtFRSW8WpRO81Kqgr9qsK6ldU&e=>
It must be that I have been reading about such things a lot recently. If it is hand crafted than it shows humans are still edging out the robots for now..
On Apr 1, 2021, at 12:18 PM, Alex Balashov <abalashov at evaristesys.com> wrote:
Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system?
? Sent from mobile, with due apologies for brevity and errors.
On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com> wrote:
?GPT-3? Happy April Fools Day.
Brandon
On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com> wrote:
?For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership with Posner | Palner Pharmaceuticals, are pleased to announce the eagerly anticipated start of Phase III clinical trials of Kamailio DMQ module replication.
In this stage of the investigation of the promising replication scheme, which was developed in record time, DMQ will be tested in a rigourous, double-blind, controlled CI/CD process for large-scale efficacy and continually monitored for safety in shorter and longer terms.
The now-concluded second phase established basic safety and Phase 2b entailed a dose-finding study for the optimal number of batched `dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will enroll 380 randomly selected, statistically representative Floridian SIP registrars and 5700 SIP dialogs, also in the state of Florida. When asked about the disparity in the number of registrars versus dialogs, Alex Balashov of Evariste said, "It is reflective of the small number of SIP registrars in Florida; not to be indelicate, but consider the median age of the population."
As previously remarked upon in proceedings of the World SIP Organisation (WSO), the choice of Florida as a venue attracted some questions. We asked Fred Posner of Posner | Palner about the clinical background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the open climate and reluctance to accept traditional data integrity science would have sealed the deal, but when people started to drink bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug Administration EUA (Emergency Use Authorisation) for DMQ replication as a prophylactic data redundancy and failover measure to ward off the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
Phase II studies have painted a promising a picture of the DMQ architecture's ability to reduce moderate to severe symptoms and associated 28-day mortality by more than 90%, albeit over a small sample size and in enterprise patients with known pre-existing comorbidities such as Session Border Controller and BroadSoft Multi-System Inflammatory Syndrome. Phase III trials seek to bolster quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard pipe-to-/dev/null placebo protocol, but with identical '200 OK' confirmation messages. We proudly developed this approach in early 2020 in consultation with the highest levels of the Trump presidential administration; it is called TENP, or 'The Emperor's New Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida Governor Ron DeSantis, Balashov was quick to provide reassurance about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within standard deviation over the mean for all insecure replication, and there's support for other transports on the way. Anyway, we have a robust adverse effects reporting system in our issue tracker and solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only replication investigation undertaken by Evariste and Posner | Palner, although it is the only prophylactic suitable for the early infection development and inflammatory phases of a broad class of SBC-complex syndromes typically afflicting service providers. A recent IETF preprint by the same authors has shown high-quality preliminary data suggesting statistically significant improvement in morbidity outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
-- Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ _______________________________________________ VoiceOps mailing list VoiceOps at voiceops.org https://puck.nether.net/mailman/listinfo/voiceops
participants (6)
-
abalashov＠evaristesys.com -
bsvec＠teamonesolutions.com -
caalvarez＠gmail.com -
David.Hiers＠cdk.com -
jhellenthal＠dataix.net -
marylou＠backuptelecom.com